SCHEMBL137832

SCHEMBL137832

O=C(CS(=O)(=O)O)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.56
MAPT P10636 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
MEN1 O00255 2/20 0.56
CYP3A4 P08684 2/20 0.56
HPGD P15428 2/20 0.56
KMT2A Q03164 2/20 0.56
KDM4E B2RXH2 1/20 0.56
ALOX15 P16050 1/20 0.56
CES1 P23141 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
RECQL P46063 2/20 0.55
ALDH1A1 P00352 4/20 0.52
GSK3B P49841 2/20 0.52
PTPN1 P18031 2/20 0.52
HIF1A Q16665 2/20 0.52
TRPA1 O75762 1/20 0.52
TSHR P16473 1/20 0.52
HSD11B1 P28845 6/20 0.50
L3MBTL1 Q9Y468 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7868384 0.98 MAPK1 (0.54) MAPK1MAPTTDP1MEN1CYP3A4
SCHEMBL9343108 0.84 ERCC5 (0.46) MAPK1MAPTTDP1MEN1CYP3A4
SCHEMBL1516246 0.84 MAPK1 (0.58) MAPK1MAPTTDP1MEN1CYP3A4
SCHEMBL11305155 0.84 KMT2A (0.59) MAPK1MAPTTDP1MEN1CYP3A4
SCHEMBL260911 0.80 ALDH1A1 (0.56) MAPK1MAPTTDP1MEN1CYP3A4
SCHEMBL9197870 0.80 MAPK1 (0.54) MAPK1MAPTTDP1MEN1CYP3A4
SCHEMBL2188285 0.80 MAPT (0.54) MAPK1MAPTTDP1MEN1CYP3A4
SCHEMBL11145720 0.80 KMT2A (0.54) MAPK1MAPTTDP1MEN1CYP3A4
SCHEMBL1699941 0.80 RECQL (0.58) MAPK1MAPTTDP1MEN1CYP3A4
SCHEMBL7149069 0.80 MAPK1 (0.54) MAPK1MAPTTDP1MEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2788353-B1 CAGE AMINE LIGANDS FOR METALLO-RADIOPHARMACEUTICALS Clarity Pharmaceuticals Ltd (AU) 2022-05-18 EP claimed
US-4616086-A ANTICOAGULANTS BOEHRINGER MANNHEIM GMBH (DE) 1986-10-07 US claimed
EP-4387944-A1 RADIOPHARMACEUTICALS, METHODS FOR THE PRODUCTION THEREOF, AND USES IN TREATMENT, DIAGNOSIS AND IMAGING DISEASES Clarity Pharmaceuticals Ltd (AU) 2024-06-26 EP disclosed
US-20240190897-A1 NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS Clarity Pharmaceuticals Ltd (AU) 2024-06-13 US disclosed
WO-2024098115-A1 COMPOUNDS FOR RADIOIMAGING AND TREATMENT OF A CANCER Clarity Pharmaceuticals Limited (AU) 2024-05-16 WO disclosed
US-11905301-B2 Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals CLARITY PHARMACEUTICALS LTD. (AU) 2024-02-20 US disclosed
WO-2024031153-A1 DIMERIC RADIOPHARMACEUTICALS, COMPOSITIONS THEREOF AND USES THEREOF Clarity Pharmaceuticals Limited (AU) 2024-02-15 WO disclosed
US-20240050600-A1 Radiopharmaceuticals, uses thereof, and methods for the production thereof Clarity Pharmaceuticals Ltd (AU) 2024-02-15 US disclosed
EP-4196175-A1 RADIOPHARMACEUTICALS, USES THEREOF, AND METHODS FOR THE PRODUCTION THEREOF Clarity Pharmaceuticals Ltd (AU) 2023-06-21 EP disclosed
WO-2023092184-A1 COMPOUNDS AND COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER Clarity Pharmaceuticals Ltd (AU) 2023-06-01 WO disclosed
WO-2023081967-A1 COMPOUNDS AND USES THEREFOR THE UNIVERSITY OF WESTERN AUSTRALIA (AU) 2023-05-19 WO disclosed
WO-2001079185-A1 NOVEL AMINO CARBOXY ALKYL DERIVATIVES OF BARBITURIC ACID CURRY KENNETH (CA) 2001-10-25 WO disclosed
EP-1071655-A1 CUBANE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND PROCESS FOR THEIR PREPARATION Curry, Kenneth (CA) 2001-01-31 EP disclosed
WO-1999054280-A1 CUBANE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND PROCESS FOR THEIR PREPARATION CURRY KENNETH (CA) 1999-10-28 WO disclosed
CN-1211237-A Process for preparing 2-(thiosubstituted)-4-haloacetophenones RHONE POULENC AGRICULTURE (GB) 1999-03-17 CN disclosed
EP-0173748-B1 PROCESS FOR PRODUCING SUBSTITUTED UNSATURATED SIX-MEMBERED RING COMPOUNDS FROM PHENOL DERIVATIVES HIRAI, Hidefumi (JP) 1990-01-03 EP disclosed
US-4663478-A Process for producing a para-substituted phenol derivative Hirai, Hidefuni 1987-05-05 US disclosed
US-4616086-A ANTICOAGULANTS BOEHRINGER MANNHEIM GMBH (DE) 1986-10-07 US disclosed
EP-0173748-A1 PROCESS FOR PRODUCING SUBSTITUTED UNSATURATED SIX-MEMBERED RING COMPOUNDS FROM PHENOL DERIVATIVES HIRAI, Hidefumi (JP) 1986-03-12 EP disclosed
US-4474809-A HYPOGLYCEMIC AGENTS, ANTIDIABETIC AGENTS AMERICAN CYANAMID COMPANY (US) 1984-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240050600-A1 Radiopharmaceuticals, uses thereof, and methods for the production thereof GRPR, OGFR, GHRHR MAPK1 4461/4885MAPT 3555/4885TDP1 4662/4885
US-11905301-B2 Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals NCL, NUDC, C3AR1 MAPK1 4380/4885MAPT 3001/4885TDP1 3518/4885
US-20240190897-A1 NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS NCL, NUDC, C3AR1 MAPK1 4380/4885MAPT 3001/4885TDP1 3518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.